

You're invited!

2025 American Foregut Society Annual Meeting

Join us for an interactive dinner symposium at the 2025 AFS Annual Meeting to learn how the LINX™ Reflux Management System continues to redefine the surgical treatment of reflux disease.



Date: Fri, 9/12/25
Time: 6:30pm

Room #: Gaylord
Texan Room,
High Planes 2-3



Mythbusters: LINX™ Myths, Truths, and Tidbits

with faculty moderator:

John Lipham, MD, FACS
USC Keck School of Medicine
Los Angeles, CA



Guest panelists and case review topics include:

Chasing Unicorns:
Post-sleeve patient
selection



Christopher DuCoin
MD, MPH, FACS
University of South Florida
Tampa, FL

**Unidentified Foregut
Options (UFOs):**
LINX™ and Barrett's
Esophagus



Michael S. Smith
MD, MBA
Mount Sinai Health Center
New York, NY

**Beasts Above the
Diaphragm:**
Hiatal hernia




Caitlin C. Houghton
MD
USC Keck School of Medicine
Los Angeles, CA

Learn more about LINX™ after sleeve gastrectomy



Scan the QR code or follow the link to see the results of the Khaitan, et al. (2023) study of patients implanted with LINX™ after sleeve gastrectomy.

<https://pubmed.ncbi.nlm.nih.gov/36471179/>



Ethicon policy limits attendance at corporate sponsored events to healthcare professionals with a bona fide professional interest in the program. Accordingly, company policy prohibits spouses, significant others, or guests from attending this event. Due to Vermont state law, Ethicon cannot provide meals to Vermont HCPs through this program. If you receive a transfer of value in association with attending this event (i.e., paid or reimbursed travel expenses, meal costs), Ethicon may be required to report such information to the U.S. government, depending on your professional license and the requirements under the Federal Open Payments Program and State Transparency Reporting laws. If you do not wish this information to be disclosed to the government, or if you are subject to any local laws or employer restrictions that prohibit you from receiving transfers of value, we request that you refrain from accepting our hospitality.

LINX™ Reflux Management System Important Safety Information The LINX Reflux Management System is a laparoscopic, fundic-sparing anti-reflux procedure indicated for patients diagnosed with Gastroesophageal Reflux Disease (GERD) as defined by abnormal pH testing, and who are seeking an alternative to continuous acid suppression therapy (i.e. proton pump inhibitors or equivalent) in the management of their GERD. **Rx Only. Contraindications:** Do not implant the LINX system in patients with suspected or known allergies to titanium, stainless steel, nickel, or ferrous materials. **Warnings:** The LINX device is considered MR Conditional in a magnetic resonance imaging (MRI) system up to either 0.7 Tesla (0.7T) or 1.5 Tesla (1.5T), depending on the LINX model implanted. Laparoscopic placement of the LINX device is major surgery. **General Precautions:** The LINX device is a long-term implant for use in patients 21 years or older. Medical management of adverse reactions may include explantation and/or replacement. Potential Risks Associated with LINX System: belching, decreased appetite, device erosion, device migration (device does not appear to be at the implant site), dysphagia (difficult swallowing), flatulence, hiccups, inability to belch or vomit, infection, nausea, odynophagia (painful swallowing), pain regurgitation, stomach bloating, weight loss, swallow-induced syncope (fainting), and worsening of preoperative symptoms. Your physician can help you determine if LINX is right for you. Patient results may vary. For full patient information visit www.linxforlife.com or www.ethicon.com. 103260-221006
© Ethicon, US LLC 2022

**Johnson & Johnson
MedTech**

Manufactured by:
Torax™ Medical, Inc.
4545 Creek Rd
Cincinnati, OH 45242

© Johnson & Johnson
and its affiliates 2025.
US_SRG_LINX_404656